Joann Hong Curtis, MD
Gastroenterology · New Haven, CTNPI 1770626483
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 212 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,453 and has fallen 98.5% since, to $21 in 2023. That places this record below the midpoint for gastroenterology clinicians in CT, where the typical reported total is $3,356.
Across 212 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$864
- Takeda Pharmaceuticals U.S.A., Inc.$743
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$581
- Johnson & Johnson$340
- QOL Medical, LLC$224
- Bristol Myers Squibb$179
- plus $933 from 16 others
What the payments were for
- Consulting fees$120%
- Food & beverage$3,852100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $864 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $743 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 39 | $581 |
| Johnson & Johnson | 20 | $340 |
| QOL Medical, LLC | 7 | $224 |
| Bristol Myers Squibb | 9 | $179 |
| Ardelyx, Inc. | 8 | $145 |
| Ferring Pharmaceuticals Inc. | 9 | $141 |
| Gilead | 6 | $103 |
| Ironwood Pharmaceuticals, Inc | 6 | $103 |
| Pfizer | 5 | $87 |
| UCB, Inc. | 4 | $63 |
| Intercept Pharmaceuticals, Inc. | 3 | $56 |
| Merck | 1 | $42 |
| Alfasigma USA, Inc. | 2 | $33 |
| Nestle Healthcare Nutrition Inc. | 1 | $29 |
| Braintree Laboratories, Inc. | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Medtronic | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $12 |
How this compares
$3,864 in reported general payments places this provider in the 50th percentile of 326 gastroenterology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 32 | $77,617 |
| LinzessLinaclotide | 53 | $43,317 |
| ZenpepLipase/Protease/Amylase | 16 | $38,459 |
| CreonLipase/Protease/Amylase | 13 | $28,534 |
| Mesalamine | 53 | $15,615 |
| Dexlansoprazole DrDexlansoprazole | 64 | $15,213 |
| TrulancePlecanatide | 13 | $7,371 |
| Famotidine | 433 | $7,327 |
| Mesalamine ErMesalamine | 30 | $6,929 |
| Lubiprostone | 21 | $6,684 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 27 | $4,376 |
| Ondansetron Hcl | 41 | $3,502 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 53 | $3,351 |
| Esomeprazole Magnesium | 72 | $3,221 |
| Lansoprazole | 42 | $2,941 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $581 | $84,98845 claims |
| AbbVieLinzess, Creon | $864 | $71,85266 claims |
| Braintree Laboratories, Inc.Sutab | $28 | $4,37627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 326 gastroenterology providers in Connecticut.
Other gastroenterology in New Haven
- Pramod MistryNew Haven$126K
- Daniel ZanchettiNew Haven$94K
- Pichamol JirapinyoNew Haven$84K
- Jill GaidosNew Haven$69K
- Myron BrandNew Haven$60K
- Harry AslanianNew Haven$52K
- James BoyerNew Haven$48K
- Thiruvengadam MunirajNew Haven$45K
- Badr Al BawardyNew Haven$42K
- Mae TigheNew Haven$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.